2012 Bioavailability and Bioequivalence: The Language of Drug Product Quality @ Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK
May 12 @ 9:00 am – 5:30 pm

BABE_12May Bioavailability (BA) and bioequivalence (BE) studies are required of new as well as generic drug products. BA/BE are parameters with practical and public health value for drug manufacturers, for regulatory agencies, and ultimately for patients. From a drug product performance perspective, BA studies also benchmark the performance of the formulation(s) used in the clinical trials. The performance of further reformulation of this product and subsequently its generic equivalent is expected to be linked to the benchmark performance of the clinical trial dosage form.

The objective of this one‐day workshop is to provide a broad perspective on the theory and practice of BA/BE, with a special emphasis on the utility of the Biopharmaceutic Classification System (BCS) as an important decision making tool for assessing drug product quality. As examples, generic drug products in Hong Kong and in Japan will be profiled according to the BCS. In addition to introducing quality‐by‐design (QbD) as a proactive strategy for incorporating critical quality attributes into drug formulation design, the workshop will conclude with an open forum on the way forward for BA/BE as the language of drug product quality in Hong Kong.

2012 ACCP – The 12th Asian Conference on Clinical Pharmacy @ Convention Hall, Level 1, Hong Kong Convention and Exhibition Centre, Hong Kong SAR, China
Jul 7 – Jul 9 all-day
2013 Hong Kong Pharmacy Conference @ Hong Kong Convention and Exhibition Centre,1 Expo Drive, Wan Chai, Hong Kong, China
Mar 23 – Mar 24 all-day
2013 Professional Development Workshop @ LT 8, Yasumoto International Academic Park (YIA), CUHK
Jun 1 @ 1:30 pm – 5:00 pm
2013 AAPS @ China Symposium @ Yasumoto International Academic Park, LT2, CUHK
Aug 17 – Aug 18 all-day
2014 Hong Kong Pharmacy Conference @ S220 Meeting Room, Hong Kong Convention & Exhibition Centre, Wanchai, Hong Kong
Mar 15 – Mar 16 all-day
2014 Huaxia Health Technology Assessment Forum @ Courtyard at Marriott Hong Kong Shatin, Hong Kong, China
Apr 26 – Apr 27 all-day

20140426ISPOR_PosterTheme: Health Technology Assessment: Impact on Health Care and Assessment of the Value of Medicines

Organizers: ISPOR Hong Kong Chapter and The Chinese University of Hong Kong

Co-organizers: ISPOR Asia Consortium, Shanghai Chapter and Beijing Chapters

2015 Hong Kong Pharmacy Conference @ S220 Meeting Room, Hong Kong Convention & Exhibition Centre, Wanchai, Hong Kong
Mar 28 – Mar 29 all-day
2015 Workshop on “Novel Delivery Platforms for Patient-centered Therapeutics” @ G02, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39 , CUHK
Jun 25 @ 8:45 am – 5:00 pm

Date: 25 June 2015 (Thursday)20150625_Novel_Banner
Venue: G02, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39 , CUHK
Time: 08:45a.m. – 5:00p.m.

Customizing drug delivery to treat patients burdened with a myriad of diseases in a therapeutically and cost effective manner while meeting the vigorous regulatory standards of quality is a formidable challenge in personalized medicine. This is underscored by the important decision making role of the patient in determining the therapeutic outcome, a phenomenon commonly referred to as adherence. The objective of this one-day workshop is to highlight multidisciplinary research intended to benefit the elderly. Professor Ping I. Lee, an eminent scholar in mass transport at the University of Toronto, will keynote the scientific principles that underline the technologies of modified drug release, including those intended for nasal, pulmonary, and direct intravitreal administration. Furthermore, patients may also benefit from research in measuring blood-brain barrier permeability and from advances in digitally-based technologies for monitoring progress in drug therapy real time. In the final analysis, formulations designed to compensate for the deterioration in postural balance, manual dexterity, swallowing, and cognitive acuity commonly seen in the elderly is a timely development. Let’s not forget China alone could have some 400 million people over 60 years of age by 2050. Therefore, the market demand for such formulations could be substantial.


2015 Nanotechnology & Advanced Materials Symposium: Advanced Biomaterials and Nanotechnologies in Drug Delivery @ Room S226 – 228, Hong Kong Convention & Exhibition Centre
Sep 25 @ 2:00 pm – 5:00 pm

Comments are closed